Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

Igor S. Lukashevich, Ricardo Carrion, Maria S. Salvato, Keith Mansfield, Kathleen Brasky, Juan Zapata, Cristiana Cairo, Marco Goicochea, Gia E. Hoosien, Anysha Ticer, Joseph Bryant, Harry Davis, Rasha Hammamieh, Maria Mayda, Marti Jett, Jean Patterson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.

Original languageEnglish (US)
Pages (from-to)5246-5254
Number of pages9
JournalVaccine
Volume26
Issue number41
DOIs
StatePublished - Sep 26 2008
Externally publishedYes

Fingerprint

Lassa Fever
Callithrix
mononuclear leukocytes
Primates
fever
Vaccination
Vaccines
immune response
vaccines
Safety
Viremia
Oligonucleotide Array Sequence Analysis
vaccination
Cellular Immunity
Blood Cells
Callithrix jacchus
Callitrichidae
viremia
Gene Expression
cell-mediated immunity

Keywords

  • Arenaviruses
  • Lassa fever
  • Protection
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Lukashevich, I. S., Carrion, R., Salvato, M. S., Mansfield, K., Brasky, K., Zapata, J., ... Patterson, J. (2008). Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine, 26(41), 5246-5254. https://doi.org/10.1016/j.vaccine.2008.07.057

Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. / Lukashevich, Igor S.; Carrion, Ricardo; Salvato, Maria S.; Mansfield, Keith; Brasky, Kathleen; Zapata, Juan; Cairo, Cristiana; Goicochea, Marco; Hoosien, Gia E.; Ticer, Anysha; Bryant, Joseph; Davis, Harry; Hammamieh, Rasha; Mayda, Maria; Jett, Marti; Patterson, Jean.

In: Vaccine, Vol. 26, No. 41, 26.09.2008, p. 5246-5254.

Research output: Contribution to journalArticle

Lukashevich, IS, Carrion, R, Salvato, MS, Mansfield, K, Brasky, K, Zapata, J, Cairo, C, Goicochea, M, Hoosien, GE, Ticer, A, Bryant, J, Davis, H, Hammamieh, R, Mayda, M, Jett, M & Patterson, J 2008, 'Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates', Vaccine, vol. 26, no. 41, pp. 5246-5254. https://doi.org/10.1016/j.vaccine.2008.07.057
Lukashevich IS, Carrion R, Salvato MS, Mansfield K, Brasky K, Zapata J et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008 Sep 26;26(41):5246-5254. https://doi.org/10.1016/j.vaccine.2008.07.057
Lukashevich, Igor S. ; Carrion, Ricardo ; Salvato, Maria S. ; Mansfield, Keith ; Brasky, Kathleen ; Zapata, Juan ; Cairo, Cristiana ; Goicochea, Marco ; Hoosien, Gia E. ; Ticer, Anysha ; Bryant, Joseph ; Davis, Harry ; Hammamieh, Rasha ; Mayda, Maria ; Jett, Marti ; Patterson, Jean. / Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. In: Vaccine. 2008 ; Vol. 26, No. 41. pp. 5246-5254.
@article{fbfaf957ab014e559bcae3dadcb704a4,
title = "Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates",
abstract = "A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.",
keywords = "Arenaviruses, Lassa fever, Protection, Vaccine",
author = "Lukashevich, {Igor S.} and Ricardo Carrion and Salvato, {Maria S.} and Keith Mansfield and Kathleen Brasky and Juan Zapata and Cristiana Cairo and Marco Goicochea and Hoosien, {Gia E.} and Anysha Ticer and Joseph Bryant and Harry Davis and Rasha Hammamieh and Maria Mayda and Marti Jett and Jean Patterson",
year = "2008",
month = "9",
day = "26",
doi = "10.1016/j.vaccine.2008.07.057",
language = "English (US)",
volume = "26",
pages = "5246--5254",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "41",

}

TY - JOUR

T1 - Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

AU - Lukashevich, Igor S.

AU - Carrion, Ricardo

AU - Salvato, Maria S.

AU - Mansfield, Keith

AU - Brasky, Kathleen

AU - Zapata, Juan

AU - Cairo, Cristiana

AU - Goicochea, Marco

AU - Hoosien, Gia E.

AU - Ticer, Anysha

AU - Bryant, Joseph

AU - Davis, Harry

AU - Hammamieh, Rasha

AU - Mayda, Maria

AU - Jett, Marti

AU - Patterson, Jean

PY - 2008/9/26

Y1 - 2008/9/26

N2 - A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.

AB - A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.

KW - Arenaviruses

KW - Lassa fever

KW - Protection

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=50949131974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949131974&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.07.057

DO - 10.1016/j.vaccine.2008.07.057

M3 - Article

C2 - 18692539

AN - SCOPUS:50949131974

VL - 26

SP - 5246

EP - 5254

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -